This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: GenVec

I hope everyone read my positive write-up yesterday of Exact Sciences (EXAS - Get Report) and its revamped stool-based gene test for colon cancer. Amazing, I know, but I am capable of being bullish on a healthcare stock. I sincerely think Exact is a compelling turnaround story.

Of course, even my positive columns get pushback. Rick A. doesn't think Exact's efforts to improve its stool-based test will matter much because patients still don't want to deal with their stool.

" I'm sorry, but compliance is the thing with colon cancer screening. Exact could have the best science in the world but if patients won't bring in their stool test kits (and they won't) nothing is gained. With a blood test, docs actually get near perfect compliance... as in 'I'm going to draw a little blood from you.' The patient goes 'OK.' It'll be just one more test on the panel. "

Enzo Biochem(ENZ) recently signed a deal with GeneNews of Canada to bring their blood-based colon cancer screening test to the U.S. the second half of this year...For me, getting patients to cooperate is 90% of taking care of them. It's amazing how they'll sit still while I stick them, but they won't play with their poop even if it will potentially save their life.

I agree that a blood-based molecular screen would be vastly preferred over one in which patients have to "play with their poop," even if just a little. I'm not familiar with the Enzo-GeneNews test, but I was under the impression that blood-based tests, to date, have not demonstrated sufficient accuracy in detecting important pre-cancerous lesions in the colon. That's something that Exact's stool-based test can do.
6 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ANX $0.73 0.00%
ALKS $39.75 -3.73%
CYCC $0.39 -7.14%
DNDN $0.06 -6.02%
EXAS $7.02 -1.54%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs